Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estetrol add-on to LHRH agonist in prostate cancer
NL-OMON46625Phase 2Active, not recruiting
- Sponsor
- Pantarhei Oncology
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Estetrol + LHRH agonist with Placebo + LHRH agonist (2 arms). Primary endpoints: Total testosterone and free testosterone suppression and Hot flushes. Started Apr 2018; status: active, not recruiting.
02
Drugs
estetrol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON46625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46625.